Search

Your search keyword '"Maggi, E"' showing total 1,109 results
Start Over Author "Maggi, E"
1,109 results on '"Maggi, E"'

2. EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count

Author

Bruno, R, Mondelli, M, Brunetti, E, Di Matteo, A, Seminari, E, Maiocchi, L, Zuccaro, V, Pagnucco, L, Mariani, B, Ludovisi, S, Lissandrin, R, Parisi, A, Sacchi, P, Patruno, SFA, Michelone, G, Gulminetti, R, Zanaboni, D, Novati, S, Maserati, R, Orsolini, P, Vecchia, M, Sciarra, M, Asperges, E, Colaneri, M, Di Filippo, A, Sambo, M, Biscarini, S, Lupi, M, Roda, S, Pieri, TC, Gallazzi, I, Sachs, M, Valsecchi, P, Perlini, S, Alfano, C, Bonzano, M, Briganti, F, Crescenzi, G, Falchi, AG, Guarnone, R, Guglielmana, B, Maggi, E, Martino, I, Pettenazza, P, Pioli di Marco, S, Quaglia, F, Sabena, A, Salinaro, F, Speciale, F, Zunino, I, De Lorenzo, M, Secco, G, Dimitry, L, Cappa, G, Maisak, I, Chiodi, B, Sciarrini, M, Barcella, B, Resta, F, Moroni, L, Vezzoni, G, Scattaglia, L, Boscolo, E, Zattera, C, Tassi, MF, Capozza, V, Vignaroli, D, Bazzini, M, Iotti, G, Mojoli, F, Belliato, M, Perotti, L, Mongodi, S, Tavazzi, G, Marseglia, G, Licari, A, Brambilla, I, Barbarini, D, Bruno, A, Cambieri, P, Campanini, G, Cavanna, C., Comolli, G, Corbella, M, Daturi, R, Furione, M, Marone, P, Monzillo, E, Paolucci, S, Parea, M, Percivalle, E, Piralla, A, Rovida, F, Sarasini, A, Zavattoni, M, Adzasehoun, G, Ardizzone, M, Bellotti, L, Brunco, V, Cabano, E, Casali, G, Capella, L, Devitis, D, Dossena, L, Frisco, G, Garbagnoli, G, Gardellini, F, Girello, A, Guerrizio, A, Landini, V, Lucchelli, C, Maliardi, V, Piemontese, P, Pezzaia, S, Premoli, M, Rebuffa, C, Zanello, C, Bagnarino, J, Bergami, F, Bonetti, A, Caneva, G, Cassaniti, I, Corcione, A, Di Martino, R, Di Napoli, A, Ferrari, A, Ferrari, G, Fiorina, L, Gallone, A, Giardina, F, Girardi, A, Mercato, A, Merla, C, Novazzi, F, Ratano, G, Rossi, B, Saveriaempillai, G, Sciabica, IM, Tallarita, M, Vecchio Nepita, E, Vitali, J, Cerino, A, Varchetta, S, Oliviero, B, Mantovani, S, Mele, D, Calvi, M, Tizzoni, M, Nicora, C, Triarico, A, Petronella, V, Marena, C, Muzzi, A, Lago, P, Cutti, S, Novelli, V, Comandatore, F, BatistiBiffignandi, G, Gaiarsa, S, Rettani, M, Bandi, C, Paolucci, Stefania, Cassaniti, Irene, Novazzi, Federica, Fiorina, Loretta, Piralla, Antonio, Comolli, Giuditta, Bruno, Raffaele, Maserati, Renato, Gulminetti, Roberto, Novati, Stefano, Mojoli, Francesco, and Baldanti, Fausto

Published
2021
Full Text
View/download PDF

8. Dim artificial light at night alters gene expression rhythms and growth in a key seagrass species (Posidonia oceanica)

Author

Dalle, Carbonare L, Basile, A, Rindi, Luca, Bulleri, F, Hamedeh, H, Iacopino, S, Shukla, V, Weits, DA, Lombardi, L, Sbrana, A, Benedetti-Cecchi, Lisandro, Giuntoli, B, Licausi, F, Maggi, E, Dalle, Carbonare L, Basile, A, Rindi, Luca, Bulleri, F, Hamedeh, H, Iacopino, S, Shukla, V, Weits, DA, Lombardi, L, Sbrana, A, Benedetti-Cecchi, Lisandro, Giuntoli, B, Licausi, F, and Maggi, E

Published
2023

13. Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56 bright CD16 - Subset

Author

Veneziani, I., Alicata, C., Pelosi, A., Landolina, N., Ricci, Beatrice, D'Oria, V., Fagotti, Anna, Scambia, Giovanni, Moretta, L., Maggi, E., Ricci B., Fagotti A. (ORCID:0000-0001-5579-335X), Scambia G. (ORCID:0000-0003-2758-1063), Veneziani, I., Alicata, C., Pelosi, A., Landolina, N., Ricci, Beatrice, D'Oria, V., Fagotti, Anna, Scambia, Giovanni, Moretta, L., Maggi, E., Ricci B., Fagotti A. (ORCID:0000-0001-5579-335X), and Scambia G. (ORCID:0000-0003-2758-1063)

Abstract

Background Toll-like receptors (TLRs) are pattern-recognition sensors mainly expressed in innate immune cells that directly recognize conserved pathogen structures (pathogen-associated molecular patterns-PAMPs). Natural killer (NK) cells have been described to express different endosomal TLRs triggered by RNA and DNA sequences derived from both viruses and bacteria. This study was addressed to establish which endosomal TLR could directly mediate NK activation and function after proper stimuli. It was also important to establish the most suitable TLR agonist to be used as adjuvant in tumor vaccines or in combined cancer immunotherapies. Methods We assessed endosomal TLR expression in total NK cells by using RT-qPCR and western blotting technique. In some experiments, we purified CD56 bright CD16 - and CD56 dim CD16 + cells subsets by using NK Cell Isolation Kit Activation marker, cytokine production, CD107a expression and cytotoxicity assay were evaluated by flow cytometry. Cytokine release was quantified by ELISA. NK cells obtained from ovarian ascites underwent the same analyses. Results Although the four endosomal TLRs (TLR3, TLR7/8, and TLR9) were uniformly expressed on CD56 bright CD16 - and CD56 dim CD16 + cell subsets, the TLR7/8 (R848), TLR3 (polyinosinic-polycytidylic acid, Poly I:C) and TLR9 (ODN2395) ligands promoted NK-cell function only in the presence of suboptimal doses of cytokines, including interleukin (IL)-2, IL-12, IL-15, and IL-18, produced in vivo by other environmental cells. We showed that R848 rather than TLR3 and TLR9 agonists primarily activated CD56 bright CD16 - NK cells by increasing their proliferation, cytokine production and cytotoxic activity. Moreover, we demonstrated that R848, which usually triggers TLR7 and TLR8 on dendritic cells, macrophages and neutrophils cells, activated CD56 bright CD16 - NK-cell subset only via TLR8. Indeed, specific TLR8 but not TLR7 agonists increased cytokine production and cytotoxic activity of CD56 br

Published
2022

15. Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma

Author

Sposato B., Scalese M., Ricci A., Rogliani P., Paggiaro P., Migliorini M. G., Di Tomassi M., Olivieri C., Perrella A., Camiciottoli G., Maselli R., Pelaia G., Busceti M. T., Sabato E., Cagnazzo M. G., Colombo F., Palumbo L., Ravazzi A., Bucca C., Caiaffa M. F., Berra A., Calabrese C., Stanziola A. A., Schino P., Di Gioacchino M., Cazzola M., Segreti A., Pastorello E. A., Scibilia G., Vianello A., Marchi M. R., Paladini L., Baglioni S., Abbritti M., Almerigogna F., Matucci A., Vultaggio A., Maggi E., Maestrelli P., Guarnieri G., Steinhilber G., Bonavia M., Rottoli P., Bargagli E., Senna G., Caminati M., Macchia L., Bellia V., Scichilone N., Novelli F., Latorre M., Vergura L., Masieri S., Rosati Y., Milanese M., Folletti I., Pio R., Pio A., Maccari U., Maggiorelli C., Scala R., Vignale L., Pulera N., Carpagnano G. E., Foschino Barbaro M. P., Sposato B., Scalese M., Ricci A., Rogliani P., Paggiaro P., Migliorini M.G., Di Tomassi M., Olivieri C., Perrella A., Camiciottoli G., Maselli R., Pelaia G., Busceti M.T., Sabato E., Cagnazzo M.G., Colombo F., Palumbo L., Ravazzi A., Bucca C., Caiaffa M.F., Berra A., Calabrese C., Stanziola A.A., Schino P., Di Gioacchino M., Cazzola M., Segreti A., Pastorello E.A., Scibilia G., Vianello A., Marchi M.R., Paladini L., Baglioni S., Abbritti M., Almerigogna F., Matucci A., Vultaggio A., Maggi E., Maestrelli P., Guarnieri G., Steinhilber G., Bonavia M., Rottoli P., Bargagli E., Senna G., Caminati M., Macchia L., Bellia V., Scichilone N., Novelli F., Latorre M., Vergura L., Masieri S., Rosati Y., Milanese M., Folletti I., Pio R., Pio A., Maccari U., Maggiorelli C., Scala R., Vignale L., Pulera N., Carpagnano G.E., Foschino Barbaro M.P., Sposato, B., Scalese, M., Ricci, A., Rogliani, P., Paggiaro, P., Migliorini, M. G., Di Tomassi, M., Olivieri, C., Perrella, A., Camiciottoli, G., Maselli, R., Pelaia, G., Busceti, M. T., Sabato, E., Cagnazzo, M. G., Colombo, F., Palumbo, L., Ravazzi, A., Bucca, C., Caiaffa, M. F., Berra, A., Calabrese, C., Stanziola, A. A., Schino, P., Di Gioacchino, M., Cazzola, M., Segreti, A., Pastorello, E. A., Scibilia, G., Vianello, A., Marchi, M. R., Paladini, L., Baglioni, S., Abbritti, M., Almerigogna, F., Matucci, A., Vultaggio, A., Maggi, E., Maestrelli, P., Guarnieri, G., Steinhilber, G., Bonavia, M., Rottoli, P., Bargagli, E., Senna, G., Caminati, M., Macchia, L., Bellia, V., Scichilone, N., Novelli, F., Latorre, M., Vergura, L., Masieri, S., Rosati, Y., Milanese, M., Folletti, I., Pio, R., Pio, A., Maccari, U., Maggiorelli, C., Scala, R., Vignale, L., Pulera, N., Carpagnano, G. E., Foschino Barbaro, M. P., and Et, Al

Subjects
Pulmonary and Respiratory Medicine, severe asthma, medicine.medical_specialty, medicine.drug_class, Severe asthma, Eosinophil, Settore MED/10 - Malattie Dell'Apparato Respiratorio, Gastroenterology, Persistence (computer science), 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Bronchodilator, allergic asthma, blood eosinophil, bronchodilator reversibility, lung function decline, severe asthma, salbutamol, Forced Expiratory Volume, medicine, Settore MED/10, Immunology and Allergy, Humans, 030212 general & internal medicine, Blood eosinophil, Lung, Genetics (clinical), Lung function, Bronchodilator Agent, allergic asthma, blood eosinophil, bronchodilator reversibility, lung function decline, salbutamol, bronchodilator agents, eosinophils, forced expiratory volume, humans, lung, airway obstruction, asthma, business.industry, Airway obstruction, medicine.disease, Asthma, Bronchodilator Agents, Airway Obstruction, Eosinophils, 030228 respiratory system, Salbutamol, Blood eosinophils, business, medicine.drug, Human
Abstract

Objective: This study analysed whether the persistence of both reversible airway obstruction (RAO) and elevated BE counts was associated to reduced asthma control and accelerated lung function decline in treated severe asthmatics. Methods: About 202 severe asthmatics were studied after 12–120months of step-5 treatment associated to anti-IgE therapy. Following treatments, reversibility tests, after inhaling 400 mcg of Salbutamol, were performed. FEV1>12% or ≤12% changes differentiated RAO+ from RAO− subjects. Blood eosinophil (BE) counts after treatment were considered. Results: Pre-/post-treatment bronchodilator FEV1% and ACT were lower (61% [50–71], 74.4% [62.5–83.7] and 20[18–22]), whereas BE were higher (380 cells/µl [170–590]) in RAO+ compared to RAO− subjects (77% [64–88], p=0.0001, 81.8% [66.1–94.3], p=0.0001, 21[18–23], p=0.045 and 230 cells/µl [80–360], p=0.003). A negative relationship between SABA-induced FEV1% changes and pre-bronchodilator FEV1% (β=−0.551%; p=0.0001) and ACT (β=−0.059; p=0.038) was found. Conversely, post-treatment BE levels were positively related (β=145.565 cells/µl; p=0.003) to FEV1>12% increases. A rising trend of pre-/post-bronchodilator FEV1% in time was observed in RAO− subjects with BE300 cells/µl reaching lower values after more than 36months of step-5 treatment (59.6% [39.9–72.1] vs 74[66.5–89.2] of RAO+ individuals with BE300 cells/µl [p=0.009]). Conclusion: Persistent SABA-induced FEV1>12%, especially when associated to BE>300 cells/ml, may be a marker of accelerated lung function decline in severe asthmatics despite maximal step-5 treatment. The highest bronchodilation associated to the lowest BE levels should be the main goal of asthma treatment to prevent such decline.

Published
2020

18. Redirecting Th2 Responses in Allergy

Author

Parronchi, P., Maggi, E., Romagnani, S., Compans, R. W., editor, Cooper, M., editor, Hogle, J. M., editor, Ito, Y., editor, Koprowski, H., editor, Melchers, F., editor, Oldstone, M., editor, Olsnes, S., editor, Potter, M., editor, Saedler, H., editor, Vogt, P. K., editor, Wagner, H., editor, Coffman, Robert L., editor, and Romagnani, Sergio, editor

Published
1999
Full Text
View/download PDF

20. Emergency Department and Out-of-Hospital Emergency System (112—AREU 118) integrated response to Coronavirus Disease 2019 in a Northern Italy centre

Author

Perlini, S., Canevari, F., Cortesi, S., Sgromo, V., Brancaglione, A., Contri, E., Pettenazza, P., Salinaro, F., Speciale, F., Sechi, G., Mare, C., Cutti, S., Novelli, V., Marena, C., Muzzi, A., Bruno, R., Palo, A., Mondelli, M. U., Brunetti, E., Di Matteo, A., Seminari, E., Maiocchi, L., Zuccaro, V., Pagnucco, L., Mariani, B., Ludovisi, S., Lissandrin, R., Parisi, A., Sacchi, P., Patruno, S. F. A., Michelone, G., Gulminetti, R., Zanaboni, D., Novati, S., Maserati, R., Orsolini, P., Vecchia, M., Sciarra, M., Asperges, E., Colaneri, M., Di Filippo, A., Sambo, M., Biscarini, S., Lupi, M., Roda, S., Pieri, T. C., Gallazzi, I., Sachs, M., Valsecchi, P., Alfano, C., Bonzano, M., Briganti, F., Crescenzi, G., Falchi, A. G., Guarnone, R., Guglielmana, B., Maggi, E., Martino, I., di Marco, S. P., Quaglia, F., Sabena, A., Zunino, I., Furlan, N., Savioli, G., De Lorenzo, M., Secco, G., Dimitry, L., Cappa, G., Maisak, I., Chiodi, B., Sciarrini, M., Barcella, B., Resta, F., Moroni, L., Vezzoni, G., Scattaglia, L., Boscolo, E., Zattera, C., Fidel, T. M., Vincenzo, C., Bazzini, M., Lago, E., Bracchi, F., Sturniolo, G., Iotti, G., Mojoli, F., Belliato, M., Perotti, L., Mongodi, S., Tavazzi, G., Marseglia, G., Licari, A., Brambilla, I., Daniela, B., Antonella, B., Patrizia, C., Giulia, C., Giuditta, C., Marta, C., Rossana, D., Milena, F., Bianca, M., Roberta, M., Enza, M., Stefania, P., Maurizio, P., Elena, P., Antonio, P., Francesca, R., Antonella, S., Maurizio, Z., Guy, A., Laura, B., Ermanna, C., Giuliana, C., Luca, D., Gabriella, F., Gabriella, G., Alessia, G., Viviana, L., Claudia, L., Valentina, M., Simona, P., Marta, P., Alice, B., Giacomo, C., Irene, C., Alfonso, C., Raffella, D. M., Annapia, D. N., Alessandro, F., Guglielmo, F., Loretta, F., Federica, G., Alessandra, M., Novazzi, Federica, Giacomo, R., Beatrice, R., Maria, S. I., Monica, T., Edoardo, V. N., Cerino, A., Varchetta, S., Oliviero, B., Mantovani, S., Mele, D., Calvi, M., Tizzoni, M., Nicora, C., Triarico, A., Petronella, V., Lago, P., Rettani, M., Comandatore, F., Bissignandi, G., Gaiarsa, S., Bandi, C., Ferrari, A., and Pasi, F.

Subjects
Emergency Medical Services, Coronavirus disease 2019 (COVID-19), Pneumonia, Viral, Population, Disease, 030204 cardiovascular system & hematology, law.invention, Hospital, 03 medical and health sciences, Patient Admission, 0302 clinical medicine, law, Health care, Pandemic, Internal Medicine, medicine, Covid-19, Emergency department, Emergency medical system, Emergency medical system organization, SARS-CoV-2, COVID-19, Coronavirus Infections, Emergency Service, Hospital, Humans, Intensive Care Units, Italy, Pandemics, Viral, 030212 general & internal medicine, education, Emergency Service, education.field_of_study, business.industry, Outbreak, Pneumonia, medicine.disease, Intensive care unit, Im - Original, Emergency Medicine, Medical emergency, business
Abstract

Since December 2019, the world has been facing the life-threatening disease, named Coronavirus disease-19 (COVID-19), recognized as a pandemic by the World Health Organization. The response of the Emergency Medicine network, integrating "out-of-hospital" and "hospital" activation, is crucial whenever the health system has to face a medical emergency, being caused by natural or human-derived disasters as well as by a rapidly spreading epidemic outbreak. We here report the Pavia Emergency Medicine network response to the COVID-19 outbreak. The "out-of-hospital" response was analysed in terms of calls, rescues and missions, whereas the "hospital" response was detailed as number of admitted patients and subsequent hospitalisation or discharge. The data in the first 5 weeks of the Covid-19 outbreak (February 21-March 26, 2020) were compared with a reference time window referring to the previous 5 weeks (January 17-February 20, 2020) and with the corresponding historical average data from the previous 5 years (February 21-March 26). Since February 21, 2020, a sudden and sustained increase in the calls to the AREU 112 system was noted (+ 440%). After 5 weeks, the number of calls and missions was still higher as compared to both the reference pre-Covid-19 period (+ 48% and + 10%, respectively) and the historical control (+ 53% and + 22%, respectively). Owing to the overflow from the neighbouring hospitals, which rapidly became overwhelmed and had to temporarily close patient access, the population served by the Pavia system more than doubled (from 547.251 to 1.135.977 inhabitants, + 108%). To minimize the possibility of intra-hospital spreading of the infection, a separate "Emergency Department-Infective Disease" was created, which evaluated 1241 patients with suspected infection (38% of total ED admissions). Out of these 1241 patients, 58.0% (n = 720) were admitted in general wards (n = 629) or intensive care unit (n = 91). To allow this massive number of admissions, the hospital reshaped many general ward Units, which became Covid-19 Units (up to 270 beds) and increased the intensive care unit beds from 32 to 60. In the setting of a long-standing continuing emergency like the present Covid-19 outbreak, the integration, interaction and team work of the "out-of-hospital" and "in-hospital" systems have a pivotal role. The present study reports how the rapid and coordinated reorganization of both might help in facing such a disaster. AREU-112 and the Emergency Department should be ready to finely tune their usual cooperation to respond to a sudden and overwhelming increase in the healthcare needs brought about by a pandemia like the current one. This lesson should shape and reinforce the future.

Published
2020

23. Elimination of Interface Energy Barriers Using Dendrimer Polyelectrolytes with Fractal Geometry

Author

Ros, E., Tom, T., Ortega, P., Martin, I., Maggi, E., Asensi, J. M., López-Vidrier, J., Saucedo, E., Bertomeu, J., Puigdollers, J., and Voz, C.

Abstract

In this work we study conjugated polyelectrolyte (CPE) films based on polyamidoamine (PAMAM) dendrimers of generations G1 and G3. These fractal macromolecules are compared to branched polyethylenimine (b-PEI) polymer using methanol as the solvent. All of these materials present a high density of amino groups, which protonated by methoxide counter-anions create strong dipolar interfaces. The vacuum level shift associated to these films on n-type silicon was 0.93 eV for b-PEI, 0.72 eV for PAMAM G1 and 1.07 eV for PAMAM G3. These surface potentials were enough to overcome Fermi level pinning, which is a typical limitation of aluminium contacts on n-type silicon. A specific contact resistance as low as 20 mΩ·cm2was achieved with PAMAM G3, in agreement with the higher surface potential of this material. Good electron transport properties were also obtained for the other materials. Proof-of-concept silicon solar cells combining vanadium oxide as a hole-selective contact with these new electron transport layers have been fabricated and compared. The solar cell with PAMAM G3 surpassed 15% conversion efficiency with an overall increase of all the photovoltaic parameters. The performance of these devices correlates with compositional and nanostructural studies of the different CPE films. Particularly, a figure-of-merit (Vσ) for CPE films that considers the number of protonated amino groups per macromolecule has been introduced. The fractal geometry of dendrimers leads to a geometric increase in the number of amino groups per generation. Thus, investigation of dendrimer macromolecules seems a very good strategy to design CPE films with enhanced charge-carrier selectivity.

Published
2023
Full Text
View/download PDF

26. Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes

Author

Sposato, B, Scalese, M, Milanese, M, Masieri, S, Cavaliere, C, Latorre, M, Scichilone, N, Ricci, A, Cresti, A, Santus, P, Olivieri, C, Perrella, A, Rogliani, P, Paggiaro, P, Migliorini, M. G, Di Tomassi, M, Camiciottoli, G, Maselli, R, Pelaia, G, Busceti, M. T, Sabato, E, Cagnazzo, M. G, Colombo, F, Palumbo, L, Ravazzi, A, Bucca, C, Caiaffa, M. F, Berra, A, Calabrese, C, Stanziola, A. A, Schino, P, Di Gioacchino, M, Cazzola, M, Segreti, A, Pastorello, E. A, Scibilia, G, Vianello, A, Marchi, M. R, Paladini, L, Baglioni, S, Abbritti, M, Almerigogna, F, Matucci, A, Vultaggio, A, Maggi, E, Maestrelli, P, Guarnieri, G, Steinhilber, G, Bonavia, M, Rottoli, P, Bargagli, E, Senna, G, Caminati, M, Macchia, L, Bellia, V, Novelli, F, Vergura, L, Rosati, Y, Folletti, I, Pio, R, Pio, A, Maccari, U, Maggiorelli, C, Scala, R, Vignale, L, Pulerà, N, Carpagnano, G. E, Foschino Barbaro, M. P, The Omalizumab Italian Study Group, Sposato, B, Scalese, M, Milanese, M, Masieri, S., Cavaliere, C, Latorre, M., Scichilone, N., Ricci, A., Cresti, A., Santus, P., Olivieri, C., Perrella, A., Rogliani, P., Paggiaro, P., Sposato, B., Migliorini, M. G., Di Tomassi, M., Camiciottoli, G., Maselli, R., Pelaia, G., Busceti, M. T., Sabato, E., Cagnazzo, M. G., Colombo, F., Palumbo, L., Ravazzi, A., Bucca, C., Caiaffa, M. F., Berra, A., Calabrese, C., Stanziola, A. A., Schino, P., Di Gioacchino, M., Cazzola, M., Segreti, A., Pastorello, E. A., Scibilia, G., Vianello, A., Marchi, M. R., Paladini, L., Baglioni, S., Abbritti, M., Almerigogna, F., Matucci, A., Vultaggio, A., Maggi, E., Maestrelli, P., Guarnieri, G., Steinhilber, G., Bonavia, M., Rottoli, P., Bargagli, E., Senna, G., Caminati, M., Macchia, L., Bellia, V., Novelli, F., Vergura, L., Scalese, M., Rosati, Y., Milanese, M., Folletti, I., Pio, R., Pio, A., Maccari, U., Maggiorelli, C., Scala, R., Vignale, L., Pulera, N., Carpagnano, G. E., Foschino Barbaro, M. P., Cavaliere, C., Sposato B., Scalese M., Milanese M., Masieri S., Cavaliere C., Latorre M., Scichilone N., Ricci A., Cresti A., Santus P., Olivieri C., Perrella A., Rogliani P., Paggiaro P., Migliorini M.G., Di Tomassi M., Camiciottoli G., Maselli R., Pelaia G., Busceti M.T., Sabato E., Cagnazzo M.G., Colombo F., Palumbo L., Ravazzi A., Bucca C., Caiaffa M.F., Berra A., Calabrese C., Stanziola A.A., Schino P., Di Gioacchino M., Cazzola M., Segreti A., Pastorello E.A., Scibilia G., Vianello A., Marchi M.R., Paladini L., Baglioni S., Abbritti M., Almerigogna F., Matucci A., Vultaggio A., Maggi E., Maestrelli P., Guarnieri G., Steinhilber G., Bonavia M., Rottoli P., Bargagli E., Senna G., Caminati M., Macchia L., Bellia V., Novelli F., Vergura L., Rosati Y., Folletti I., Pio R., Pio A., Maccari U., Maggiorelli C., Scala R., Vignale L., Pulera N., Carpagnano G.E., and Foschino Barbaro M.P.

Subjects
Adult, Male, medicine.medical_specialty, Settore MED/09 - Medicina Interna, Treatment outcome, MEDLINE, Omalizumab, Settore MED/10 - Malattie Dell'Apparato Respiratorio, Immunoglobulin E, eosinophil, Omalizumab, anti-IgE, asthma, Leukocyte Count, Text mining, Forced Expiratory Volume, Internal medicine, Eosinophilia, medicine, Humans, Immunology and Allergy, Anti-Asthmatic Agents, Blood eosinophil, Aged, Retrospective Studies, Asthma, biology, business.industry, Retrospective cohort study, Middle Aged, asthma, Prognosis, medicine.disease, Eosinophils, Treatment Outcome, inflammation, biology.protein, Female, business, medicine.drug
Published
2019

28. Validity of Automated Threshold Audiometry: A Systematic Review and Meta-Analysis

Author

De Wet Swanepoel, Robert H. Eikelboom, Maggi E. Soer, and Faheema Mahomed

Subjects
Engineering, medicine.medical_specialty, Absolute threshold of hearing, medicine.diagnostic_test, business.industry, Hearing loss, Reproducibility of Results, Auditory Threshold, Gold standard (test), Audiology, Speech and Hearing, Bone conduction, Systematic review, Otorhinolaryngology, Meta-analysis, medicine, Audiometry, Pure-Tone, Humans, medicine.symptom, Audiometry, business, Psychology, Hearing Loss, Reliability (statistics)
Abstract

Objectives A systematic literature review and meta-analysis on the validity (test-retest reliability and accuracy) of automated threshold audiometry compared with the gold standard of manual threshold audiometry was conducted. Design A systematic literature review was completed in peer-reviewed databases on automated compared with manual threshold audiometry. Subsequently a meta-analysis was conducted on the validity of automated audiometry. Methods A multifaceted approach, covering several databases and using different search strategies was used to ensure comprehensive coverage and to cross-check search findings. Databases included: MEDLINE, Scopus, and PubMed; a secondary search strategy was the review of references from identified reports. Reports including within-subject comparisons of manual and automated threshold audiometry were selected according to inclusion/exclusion criteria before data were extracted. For the meta-analysis weighted mean differences (and standard deviations) on test-retest reliability for automated compared with manual audiometry were determined to assess the validity of automated threshold audiometry. Results In total, 29 reports on automated audiometry (method of limits and the method of adjustment techniques) met the inclusion criteria and were included in this review. Most reports included data on adult populations using air conduction testing with limited data on children, bone conduction testing and the effects of hearing status on automated audiometry. Meta-analysis test-retest reliability for automated audiometry was within typical test-retest variability for manual audiometry. Accuracy results on the meta-analysis indicated overall average differences between manual and automated air conduction audiometry (0.4 dB, 6.1 SD) to be comparable with test-retest differences for manual (1.3 dB, 6.1 SD) and automated (0.3 dB, 6.9 SD) audiometry. No significant differences (p > 0.01; summarized data analysis of variance) were seen in any of the comparisons between test-retest reliability of manual and automated audiometry compared with differences between manual and automated audiometry. Conclusion Automated audiometry provides an accurate measure of hearing threshold, but validation data are still limited for (1) automated bone conduction audiometry; (2) automated audiometry in children and difficult-to-test populations and; (3) different types and degrees of hearing loss.

Published
2021

29. Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium

Author

Rup, B., Pallardy, M., Sikkema, D., Albert, T., Allez, M., Broet, P., Carini, C., Creeke, P., Davidson, J., De Vries, N., Finco, D., Fogdell-Hahn, A., Havrdova, E., Hincelin-Mery, A., Holland, M. C., Jensen, P. E. H., Jury, E. C., Kirby, H., Kramer, D., Lacroix-Desmazes, S., Legrand, J., Maggi, E., Maillère, B., Mariette, X., Mauri, C., Mikol, V., Mulleman, D., Oldenburg, J., Paintaud, G., Pedersen, C. R., Ruperto, N., Seitz, R., Spindeldreher, S., and Deisenhammer, F.

Published
2015
Full Text
View/download PDF

31. Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma

Author

Tumino, N., Weber, G., Besi, F., Del Bufalo, F., Bertaina, V., Paci, P., Quatrini, L., Antonucci, L., Sinibaldi, M., Quintarelli, C., Maggi, E., De Angelis, B., Locatelli, Franco, Moretta, L., Vacca, P., Caruana, I., Locatelli F. (ORCID:0000-0002-7976-3654), Tumino, N., Weber, G., Besi, F., Del Bufalo, F., Bertaina, V., Paci, P., Quatrini, L., Antonucci, L., Sinibaldi, M., Quintarelli, C., Maggi, E., De Angelis, B., Locatelli, Franco, Moretta, L., Vacca, P., Caruana, I., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

The outcome of patients affected by high-risk or metastatic neuroblastoma (NB) remains grim, with ≥ 50% of the children experiencing relapse or progression of the disease despite multimodal, intensive treatment. In order to identify new strategies to improve the overall survival and the quality of life of these children, we recently developed and optimized a third-generation GD2-specific chimeric antigen receptor (CAR) construct, which is currently under evaluation in our Institution in a phase I/II clinical trial (NCT03373097) enrolling patients with relapsed/refractory NB. We observed that our CAR T-cells are able to induce marked tumor reduction and even achieve complete remission with a higher efficiency than that of other CAR T-cells reported in previous studies. However, often responses are not sustained and relapses occur. Here, we demonstrate for the first time a mechanism of resistance to GD2.CAR T-cell treatment, showing how polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) increase in the peripheral blood (PB) of NB patients after GD2.CAR T-cell treatment in case of relapse and loss of response. In vitro, isolated PMN-MDSC demonstrate to inhibit the anti-tumor cytotoxicity of different generations of GD2.CAR T-cells. Gene-expression profiling of GD2.CAR T-cells “conditioned” with PMN-MDSC shows downregulation of genes involved in cell activation, signal transduction, inflammation and cytokine/chemokine secretion. Analysis of NB gene-expression dataset confirms a correlation between expression of these genes and patient outcome. Moreover, in patients treated with GD2.CAR T-cells, the frequency of circulating PMN-MDSC inversely correlates with the levels of GD2.CAR T-cells, resulting more elevated in patients who did not respond or lost response to the treatment. The presence and the frequency of PMN-MDSC in PB of high-risk and metastatic NB represents a useful prognostic marker to predict the response to GD2.CAR T-cells and other adoptive immun

Published
2021

32. Severe asthma: One disease and multiple definitions

Author

Bagnasco, D., Paggiaro, P., Latorre, M., Folli, C., Testino, E., Bassi, A., Milanese, M., Heffler, E., Manfredi, A., Riccio, A. M., De Ferrari, L., Blasi, F., Canevari, R. F., Canonica, G. W., Passalacqua, G., Guarnieri, G., Patella, V., Maria Pia, F. B., Carpagnano, G. E., Colle, A. D., Scioscia, G., Gerolamo, P., Puggioni, F., Racca, F., Favero, E., Iannacone, S., Savi, E., Montagni, M., Camiciottoli, G., Allegrini, C., Lombardi, Celestino Pio, Spadaro, G., Detoraki, C., Menzella, F., Galeone, C., Ruggiero, P., Yacoub, M. R., Berti, Andrea, Scichilone, N., Durante, C., Costantino, M. T., Roncallo, C., Braschi, M., D'Adda, A., Ridolo, E., Triggiani, M., Parente, R., Maria, D. A., Verrillo, M. V., Rolla, G., Brussino, L., Frazzetto, A. V., Cristina, Z. M., Lilli, M., Crimi, N., Bonavia, M., Corsico, A. G., Grosso, A., Del Giacco, S., Deidda, M., Ricciardi, L., Isola, S., Cicero, F., Amato, G., Vita, F., Spanevello, A., Pignatti, P., Cherubino, F., Visca, D., Massimo Ricciardolo, F. L., Anna Carriero, V. M., Bertolini, Francesca, Santus, P., Barlassina, R., Airoldi, A., Guida, Maria Grazia, Nucera, Eleonora, Aruanno, A., Rizzi, Angela, Caruso, Cristiano, Colantuono, S., Senna, G., Caminati, M., Arcolaci, A., Vianello, A., Bianchi, F. C., Marchi, M. R., Centanni, S., Luraschi, S., Ruggeri, S., Rinaldo, R., Parazzini, E., Calabrese, Anna Chiara, Flora, M., Cosmi, L., Di Pietro, L., Maggi, E., Pini, L., Macchia, L., Di Bona, D., Richeldi, Luca, Condoluci, Carola, Fuso, Leonello, Bonini, Matteo, Farsi, A., Carli, G., Montuschi, Paolo, Santini, G., Conte, M. E., Turchet, E., Barbetta, C., Mazza, F., D'Alo, S., Pucci, S., Caiaffa, M. F., Minenna, E., D'Elia, L., Pasculli, C., Viviano, V., Tarsia, P., Rolo, J., Di Proietto, M., Lo Cicero, Stefano, Lombardi C. (ORCID:0000-0001-8910-6693), Berti A., Bertolini F., Guida G., Eleonora Nucera. (ORCID:0000-0002-0565-7680), Rizzi A. (ORCID:0000-0002-6795-746X), Caruso C., Calabrese C., Richeldi L. (ORCID:0000-0001-8594-1448), Condoluci C., Fuso L. (ORCID:0000-0002-1198-6712), Bonini M. (ORCID:0000-0002-3042-0765), Montuschi P. (ORCID:0000-0001-5589-1750), Lo Cicero S., Bagnasco, D., Paggiaro, P., Latorre, M., Folli, C., Testino, E., Bassi, A., Milanese, M., Heffler, E., Manfredi, A., Riccio, A. M., De Ferrari, L., Blasi, F., Canevari, R. F., Canonica, G. W., Passalacqua, G., Guarnieri, G., Patella, V., Maria Pia, F. B., Carpagnano, G. E., Colle, A. D., Scioscia, G., Gerolamo, P., Puggioni, F., Racca, F., Favero, E., Iannacone, S., Savi, E., Montagni, M., Camiciottoli, G., Allegrini, C., Lombardi, Celestino Pio, Spadaro, G., Detoraki, C., Menzella, F., Galeone, C., Ruggiero, P., Yacoub, M. R., Berti, Andrea, Scichilone, N., Durante, C., Costantino, M. T., Roncallo, C., Braschi, M., D'Adda, A., Ridolo, E., Triggiani, M., Parente, R., Maria, D. A., Verrillo, M. V., Rolla, G., Brussino, L., Frazzetto, A. V., Cristina, Z. M., Lilli, M., Crimi, N., Bonavia, M., Corsico, A. G., Grosso, A., Del Giacco, S., Deidda, M., Ricciardi, L., Isola, S., Cicero, F., Amato, G., Vita, F., Spanevello, A., Pignatti, P., Cherubino, F., Visca, D., Massimo Ricciardolo, F. L., Anna Carriero, V. M., Bertolini, Francesca, Santus, P., Barlassina, R., Airoldi, A., Guida, Maria Grazia, Nucera, Eleonora, Aruanno, A., Rizzi, Angela, Caruso, Cristiano, Colantuono, S., Senna, G., Caminati, M., Arcolaci, A., Vianello, A., Bianchi, F. C., Marchi, M. R., Centanni, S., Luraschi, S., Ruggeri, S., Rinaldo, R., Parazzini, E., Calabrese, Anna Chiara, Flora, M., Cosmi, L., Di Pietro, L., Maggi, E., Pini, L., Macchia, L., Di Bona, D., Richeldi, Luca, Condoluci, Carola, Fuso, Leonello, Bonini, Matteo, Farsi, A., Carli, G., Montuschi, Paolo, Santini, G., Conte, M. E., Turchet, E., Barbetta, C., Mazza, F., D'Alo, S., Pucci, S., Caiaffa, M. F., Minenna, E., D'Elia, L., Pasculli, C., Viviano, V., Tarsia, P., Rolo, J., Di Proietto, M., Lo Cicero, Stefano, Lombardi C. (ORCID:0000-0001-8910-6693), Berti A., Bertolini F., Guida G., Eleonora Nucera. (ORCID:0000-0002-0565-7680), Rizzi A. (ORCID:0000-0002-6795-746X), Caruso C., Calabrese C., Richeldi L. (ORCID:0000-0001-8594-1448), Condoluci C., Fuso L. (ORCID:0000-0002-1198-6712), Bonini M. (ORCID:0000-0002-3042-0765), Montuschi P. (ORCID:0000-0001-5589-1750), and Lo Cicero S.

Abstract

Introduction: There is, so far, no universal definition of severe asthma. This definition usually relies on: number of exacerbations, inhaled therapy, need for oral corticosteroids, and respiratory function. The use of such parameters varies in the different definitions used. Thus, according to the parameters chosen, each patient may result in having severe asthma or not. The aim of this study was to evaluate how the choice of a specific definition of severe asthma can change the allocation of patients. Methods: Data collected from the Severe Asthma Network Italy (SANI) registry were analyzed. All the patients included were then reclassified according to the definitions of U-BIOPRED, NICE, WHO, ATS/ERS, GINA, ENFUMOSA, and TENOR. Results: 540 patients, were extracted from the SANI database. We observed that 462 (86%) met the ATS/ERS criteria as well as the GINA criteria, 259 (48%) the U-Biopred, 222 (41%) the NICE, 125 (23%) the WHO, 313 (58%) the Enfumosa, and 251 (46%) the TENOR criteria. The mean eosinophil value were similar in the ATS/ERS, U-Biopred, and Enfumosa (528, 532 and 516 cells/mcl), higher in WHO and Tenor (567 and 570 cells/mcl) and much higher in the NICE classification (624 cells/mcl). Lung function tests resulted similarly in all groups, with WHO (67%) and ATS/ERS-GINA (73%), respectively, showing the lower and upper mean FEV1 values. Conclusions: The present observations clearly evidence the heterogeneity in the distribution of patients when different definitions of severe asthma are used. However, the recent definition of severe asthma, provided by the GINA document, is similar to that indicated in 2014 by ATS/ERS, allowing mirror reclassification of the patients examined. This lack of homogeneity could complicate the access to biological therapies. The definition provided by the GINA document, which reflects what suggested by ATS/ERS, could partially overcome the problem.

Published
2021

33. Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

Author

Bagnasco, D., Povero, M., Pradelli, L., Brussino, L., Rolla, G., Caminati, M., Menzella, F., Heffler, E., Canonica, G. W., Paggiaro, P., Senna, G., Milanese, M., Lombardi, C., Bucca, C., Manfredi, A., Canevari, R. F., Passalacqua, G., Guarnieri, G., Patella, V., Maria Pia, F. B., Carpagnano, E., Colle, A. D., Scioscia, G., Gerolamo, P., Latorre, M., Puggioni, F., Racca, F., Favero, E., Iannacone, S., Savi, E., Montagni, M., Camiciottoli, G., Allegrini, C., Spadaro, G., Detoraki, C., Galeone, C., Ruggiero, P., Yacoub, M. R., Berti, Andrea, Colombo, G., Scichilone, N., Durante, C., Costantino, M. T., Roncallo, C., Braschi, M., Blasi, F., D'Adda, A., Ridolo, E., Triggiani, M., Parente, R., Maria, D. A., Verrillo, M. V., Cristina, Z. M., Lilli, M., Crimi, N., Bonavia, M., Corsico, A. G., Grosso, A., Del Giacco, S., Deidda, M., Ricciardi, L., Isola, S., Cicero, F., Amato, G., Vita, F., Spanevello, A., Pignatti, P., Cherubino, F., Visca, D., Aletti, E., Massimo Ricciardolo, F. L., Anna Carriero, V. M., Bertolini, Francesca, Santus, P., Barlassina, R., Airoldi, A., Guida, Maria Grazia, Nucera, Eleonora, Aruanno, A., Rizzi, Angela, Caruso, C., Colantuono, S., Arcolaci, A., Vianello, A., Bianchi, F. C., Marchi, M. R., Centanni, S., Luraschi, S., Ruggeri, S., Rinaldo, R., Parazzini, E., Calabrese, Anna Chiara, Flora, M., Cosmi, L., Di Pietro, L., Maggi, E., Pini, L., Macchia, L., Di Bona, D., Richeldi, Luca, Condoluci, Carola, Fuso, Leonello, Bonini, Matteo, Farsi, A., Carli, G., Montuschi, Paolo, Santini, G., Conte, M. E., Turchet, E., Barbetta, C., Mazza, F., D'Alo, S., Pucci, S., Caiaffa, M. F., Minenna, E., D'Elia, L., Pasculli, C., Viviano, V., Tarsia, P., Rolo, J., Di Proietto, M., Lo Cicero, Stefano, Berti A., Bertolini F., Guida G., Eleonora N. (ORCID:0000-0002-0565-7680), Rizzi A. (ORCID:0000-0002-6795-746X), Calabrese C., Richeldi L. (ORCID:0000-0001-8594-1448), Condoluci C., Fuso L. (ORCID:0000-0002-1198-6712), Bonini M. (ORCID:0000-0002-3042-0765), Montuschi P. (ORCID:0000-0001-5589-1750), Lo Cicero S., Bagnasco, D., Povero, M., Pradelli, L., Brussino, L., Rolla, G., Caminati, M., Menzella, F., Heffler, E., Canonica, G. W., Paggiaro, P., Senna, G., Milanese, M., Lombardi, C., Bucca, C., Manfredi, A., Canevari, R. F., Passalacqua, G., Guarnieri, G., Patella, V., Maria Pia, F. B., Carpagnano, E., Colle, A. D., Scioscia, G., Gerolamo, P., Latorre, M., Puggioni, F., Racca, F., Favero, E., Iannacone, S., Savi, E., Montagni, M., Camiciottoli, G., Allegrini, C., Spadaro, G., Detoraki, C., Galeone, C., Ruggiero, P., Yacoub, M. R., Berti, Andrea, Colombo, G., Scichilone, N., Durante, C., Costantino, M. T., Roncallo, C., Braschi, M., Blasi, F., D'Adda, A., Ridolo, E., Triggiani, M., Parente, R., Maria, D. A., Verrillo, M. V., Cristina, Z. M., Lilli, M., Crimi, N., Bonavia, M., Corsico, A. G., Grosso, A., Del Giacco, S., Deidda, M., Ricciardi, L., Isola, S., Cicero, F., Amato, G., Vita, F., Spanevello, A., Pignatti, P., Cherubino, F., Visca, D., Aletti, E., Massimo Ricciardolo, F. L., Anna Carriero, V. M., Bertolini, Francesca, Santus, P., Barlassina, R., Airoldi, A., Guida, Maria Grazia, Nucera, Eleonora, Aruanno, A., Rizzi, Angela, Caruso, C., Colantuono, S., Arcolaci, A., Vianello, A., Bianchi, F. C., Marchi, M. R., Centanni, S., Luraschi, S., Ruggeri, S., Rinaldo, R., Parazzini, E., Calabrese, Anna Chiara, Flora, M., Cosmi, L., Di Pietro, L., Maggi, E., Pini, L., Macchia, L., Di Bona, D., Richeldi, Luca, Condoluci, Carola, Fuso, Leonello, Bonini, Matteo, Farsi, A., Carli, G., Montuschi, Paolo, Santini, G., Conte, M. E., Turchet, E., Barbetta, C., Mazza, F., D'Alo, S., Pucci, S., Caiaffa, M. F., Minenna, E., D'Elia, L., Pasculli, C., Viviano, V., Tarsia, P., Rolo, J., Di Proietto, M., Lo Cicero, Stefano, Berti A., Bertolini F., Guida G., Eleonora N. (ORCID:0000-0002-0565-7680), Rizzi A. (ORCID:0000-0002-6795-746X), Calabrese C., Richeldi L. (ORCID:0000-0001-8594-1448), Condoluci C., Fuso L. (ORCID:0000-0002-1198-6712), Bonini M. (ORCID:0000-0002-3042-0765), Montuschi P. (ORCID:0000-0001-5589-1750), and Lo Cicero S.

Abstract

Background and aims: Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ health and increase healthcare spending. Aim of this study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treatment of these patients. Methods: Patients >18 years old, referred to 8 asthma clinics, starting MEP between May 2017 and December 2018, were enrolled and followed-up for 12 months. Information in the 12 months before mepolizumab were collected retrospectively. The evaluation parameters included: OCS use, number of exacerbations/hospitalizations, concomitant therapies, comorbidity, and annual number of working days lost due to the disease. The primary objective was to compare the annual total cost per patient pre- and post-MEP. Secondary outcomes included rates of exacerbations and number of OCS-dependent patients. Results: 106 patients were enrolled in the study: 46 male, median age 58 years. Mean annual cost pre- and post-MEP (cost of biologic excluded) was €3996 and €1,527, respectively. Total savings due to MEP resulted in €2469 (95%CI 1945–2993), 62% due to exacerbations reduction and 33% due to productivity increase. Such savings could fund about 22% of the total cost of MEP for one year. The introduction of MEP induced a clinical benefit by reducing both OCS-dependent patients (OR = 0.12, 95%CI 0.06–0.23) and exacerbation rate (RR = 0.19, 95%CI 0.15–0.24). Conclusions: Patients with severe eosinophilic asthma experienced a clinical benefit in asthma control adding MEP to standard therapy. Biologic therapy can be, partially, funded by the savings produced by patients’ improvement.

Published
2021

36. Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing CoVID19 epidemics in Lombardy

Author

Bruno, R., Mondelli, M., Brunetti, E., Di Matteo, A., Seminari, E., Maiocchi, L., Zuccaro, V., Pagnucco, L., Mariani, B., Ludovisi, S., Lissandrin, R., Parisi, A., Sacchi, P., Patruno, S.F.A., Michelone, G., Gulminetti, R., Zanaboni, D., Novati, S., Maserati, R., Orsolini, P., Vecchia, M., Sciarra, M., Asperges, E., Colaneri, M., Di Filippo, A., Sambo, M., Biscarini, S., Lupi, M., Roda, S., Pieri, T.C., Gallazzi, I., Sachs, M., Valsecchi, P., Perlini, S., Alfano, C., Bonzano, M., Briganti, F., Crescenzi, G., Falchi, A.G., Guarnone, R., Guglielmana, B., Maggi, E., Martino, I., Pettenazza, P., Pioli di Marco, S., Quaglia, F., Sabena, A., Salinaro, F., Speciale, F., Zunino, I., De Lorenzo, M., Secco, G., Dimitry, L., Cappa, G., Maisak, I., Chiodi, B., Sciarrini, M., Barcella, B., Resta, F., Moroni, L., Vezzoni, G., Scattaglia, L., Boscolo, E., Zattera, C., Tassi, M.F., Capozza, V., Vignaroli, D., Bazzini, M., Iotti, G., Mojoli, F., Belliato, M., Perotti, L., Mongodi, S., Tavazzi, G., Marseglia, G., Licari, A., Brambilla, I., Barbarini, D., Bruno, A., Cambieri, P., Campanini, G., Comolli, G., Corbella, M., Daturi, R., Furione, M., Monzillo, E., Paolucci, S., Parea, M., Percivalle, E., Piralla, A., Rovida, F., Sarasini, A., Zavattoni, M., Adzasehoun, G., Bellotti, L., Cabano, E., Casali, G., Dossena, L., Frisco, G., Garbagnoli, G., Girello, A., Landini, V., Lucchelli, C., Maliardi, V., Pezzaia, S., Premoli, M., Bonetti, A., Caneva, G., Cassaniti, I., Corcione, A., Di Martino, R., Di Napoli, A., Ferrari, A., Ferrari, G., Fiorina, L., Giardina, F., Mercato, A., Novazzi, F., Ratano, G., Rossi, B., Sciabica, I.M., Tallarita, M., Vecchio Nepita, E., Calvi, M., Tizzoni, M., Nicora, C., Triarico, A., Petronella, V., Marena, C., Muzzi, A., Lago, P., Cereda, D., Marseglia, G.L., and Baldanti, F.

Published
2020
Full Text
View/download PDF

39. EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count

Author

Paolucci, Stefania, primary, Cassaniti, Irene, additional, Novazzi, Federica, additional, Fiorina, Loretta, additional, Piralla, Antonio, additional, Comolli, Giuditta, additional, Bruno, Raffaele, additional, Maserati, Renato, additional, Gulminetti, Roberto, additional, Novati, Stefano, additional, Mojoli, Francesco, additional, Baldanti, Fausto, additional, Bruno, R, additional, Mondelli, M, additional, Brunetti, E, additional, Di Matteo, A, additional, Seminari, E, additional, Maiocchi, L, additional, Zuccaro, V, additional, Pagnucco, L, additional, Mariani, B, additional, Ludovisi, S, additional, Lissandrin, R, additional, Parisi, A, additional, Sacchi, P, additional, Patruno, SFA, additional, Michelone, G, additional, Gulminetti, R, additional, Zanaboni, D, additional, Novati, S, additional, Maserati, R, additional, Orsolini, P, additional, Vecchia, M, additional, Sciarra, M, additional, Asperges, E, additional, Colaneri, M, additional, Di Filippo, A, additional, Sambo, M, additional, Biscarini, S, additional, Lupi, M, additional, Roda, S, additional, Pieri, TC, additional, Gallazzi, I, additional, Sachs, M, additional, Valsecchi, P, additional, Perlini, S, additional, Alfano, C, additional, Bonzano, M, additional, Briganti, F, additional, Crescenzi, G, additional, Falchi, AG, additional, Guarnone, R, additional, Guglielmana, B, additional, Maggi, E, additional, Martino, I, additional, Pettenazza, P, additional, Pioli di Marco, S, additional, Quaglia, F, additional, Sabena, A, additional, Salinaro, F, additional, Speciale, F, additional, Zunino, I, additional, De Lorenzo, M, additional, Secco, G, additional, Dimitry, L, additional, Cappa, G, additional, Maisak, I, additional, Chiodi, B, additional, Sciarrini, M, additional, Barcella, B, additional, Resta, F, additional, Moroni, L, additional, Vezzoni, G, additional, Scattaglia, L, additional, Boscolo, E, additional, Zattera, C, additional, Tassi, MF, additional, Capozza, V, additional, Vignaroli, D, additional, Bazzini, M, additional, Iotti, G, additional, Mojoli, F, additional, Belliato, M, additional, Perotti, L, additional, Mongodi, S, additional, Tavazzi, G, additional, Marseglia, G, additional, Licari, A, additional, Brambilla, I, additional, Barbarini, D, additional, Bruno, A, additional, Cambieri, P, additional, Campanini, G, additional, Cavanna, C., additional, Comolli, G, additional, Corbella, M, additional, Daturi, R, additional, Furione, M, additional, Marone, P, additional, Monzillo, E, additional, Paolucci, S, additional, Parea, M, additional, Percivalle, E, additional, Piralla, A, additional, Rovida, F, additional, Sarasini, A, additional, Zavattoni, M, additional, Adzasehoun, G, additional, Ardizzone, M, additional, Bellotti, L, additional, Brunco, V, additional, Cabano, E, additional, Casali, G, additional, Capella, L, additional, Devitis, D, additional, Dossena, L, additional, Frisco, G, additional, Garbagnoli, G, additional, Gardellini, F, additional, Girello, A, additional, Guerrizio, A, additional, Landini, V, additional, Lucchelli, C, additional, Maliardi, V, additional, Piemontese, P, additional, Pezzaia, S, additional, Premoli, M, additional, Rebuffa, C, additional, Zanello, C, additional, Bagnarino, J, additional, Bergami, F, additional, Bonetti, A, additional, Caneva, G, additional, Cassaniti, I, additional, Corcione, A, additional, Di Martino, R, additional, Di Napoli, A, additional, Ferrari, A, additional, Ferrari, G, additional, Fiorina, L, additional, Gallone, A, additional, Giardina, F, additional, Girardi, A, additional, Mercato, A, additional, Merla, C, additional, Novazzi, F, additional, Ratano, G, additional, Rossi, B, additional, Saveriaempillai, G, additional, Sciabica, IM, additional, Tallarita, M, additional, Vecchio Nepita, E, additional, Vitali, J, additional, Cerino, A, additional, Varchetta, S, additional, Oliviero, B, additional, Mantovani, S, additional, Mele, D, additional, Calvi, M, additional, Tizzoni, M, additional, Nicora, C, additional, Triarico, A, additional, Petronella, V, additional, Marena, C, additional, Muzzi, A, additional, Lago, P, additional, Cutti, S, additional, Novelli, V, additional, Comandatore, F, additional, BatistiBiffignandi, G, additional, Gaiarsa, S, additional, Rettani, M, additional, and Bandi, C, additional

Published
2021
Full Text
View/download PDF

41. Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit

Author

Colaneri, M., Seminari, E., Novati, S., Asperges, E., Biscarini, S., Piralla, A., Percivalle, E., Cassaniti, I., Baldanti, F., Bruno, R., Mondelli, M. U., Brunetti, E., Di Matteo, A., Maiocchi, L., Zuccaro, V., Pagnucco, L., Ludovisi, S., Lissandrin, R., Parisi, A., Sacchi, P., Patruno, S. F. A., Michelone, G., Gulminetti, R., Zanaboni, D., Maserati, R., Orsolini, P., Vecchia, M., Di Filippo, A., Sambo, M., Lupi, M., Roda, S., Pieri, T. C., Gallazzi, I., Sachs, M., Valsecchi, P., Perlini, S., Alfano, C., Bonzano, M., Briganti, F., Crescenzi, G., Falchi, A. G., Guarnone, R., Guglielmana, B., Maggi, E., Martino, I., Pettenazza, P., di Marco, S. P., Quaglia, F., Sabena, A., Salinaro, F., Speciale, F., Zunino, I., de Lorenzo, M., Secco, G., Dimitry, L., Cappa, G., Maisak, I., Chiodi, B., Sciarrini, M., Barcella, B., Resta, F., Moroni, L., Vezzoni, G., Scattaglia, L., Boscolo, E., Zattera, C., Fidel, T. M., Vincenzo, C., Vignaroli, D., Bazzini, M., Iotti, G., Mojoli, F., Belliato, M., Perotti, L., Mongodi, S., Tavazzi, G., Marseglia, G., Licari, A., Brambilla, I., Barbarini, D., Bruno, A., Cambieri, P., Campanini, G., Cavanna, C., Comolli, G., Corbella, M., Daturi, R., Furione, M., Mariani, B., Marone, P., Monzillo, V., Paolucci, S., Parea, M., Rovida, F., Sarasini, A., Zavattoni, M., Adzasehoun, G., Ardizzone, M., Bellotti, L., Brunco, V., Cabano, E., Casali, G., Capella, L., Devitis, D., Dossena, L., Frisco, G., Garbagnoli, G., Gardellini, F., Girello, A., Guerrizio, A., Landini, V., Lucchelli, C., Maliardi, V., Piemontese, P., Pezzaia, S., Premoli, M., Rebuffa, C., Bagnarino, J., Bergami, F., Bonetti, A., Caneva, G., Corcione, A., Di Martino, R., Di Napoli, A., Ferrari, A., Ferrari, G., Fiorina, L., Gallone, A., Giardina, F., Girardi, A., Mercato, A., Novazzi, F., Ratano, G., Rossi, B., Saverimpilla, G., Sciabica, I. M., Tallarita, M., Nepita, E. V., Vitali, J., Cerino, A., Varchetta, S., Oliviero, B., Mantovani, S., Mele, D., Calvi, M., Tizzoni, M., Nicola, C., Triarico, A., Petronella, V., Marena, C., Muzzi, A., Lago, P., Comandatore, F., Biffignandi, G. B., Gaiarsa, S., Rettani, M., and Bandi, C.

Subjects
0301 basic medicine, Microbiology (medical), Environmental contamination, medicine.medical_treatment, 030106 microbiology, Microbiology, Coronavirus disease 2019, Severe acute respiratory syndrome coronavirus-2, Surfaces, Vero E6 cells, Animals, Betacoronavirus, Chlorocebus aethiops, Coronavirus Envelope Proteins, Equipment Contamination, Fomites, Humans, Intensive Care Units, Microbial Viability, RNA-Dependent RNA Polymerase, Reverse Transcriptase Polymerase Chain Reaction, SARS-CoV-2, Vero Cells, Viral Envelope Proteins, Viral Proteins, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, RNA polymerase, medicine, 030212 general & internal medicine, Continuous positive airway pressure, Respiratory system, Gene, Cytopathic effect, business.industry, RNA, General Medicine, Infectious Diseases, chemistry, Vero cell, business
Abstract

Objectives To detect possible severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) RNA contamination of inanimate surfaces in areas at high risk of aerosol formation by patients with coronavirus disease 2019 (COVID-19). Methods Sampling was performed in the emergency unit and the sub-intensive care ward. SARS-CoV-2 RNA was extracted from swabbed surfaces and objects and subjected to real-time RT-PCR targeting RNA-dependent RNA polymerase and E genes. Virus isolation from positive samples was attempted in vitro on Vero E6 cells. Results Twenty-six samples were collected and only two were positive for low-level SARS-CoV-2 RNA, both collected on the external surface of continuous positive airway pressure helmets. All transport media were inoculated onto susceptible cells, but none induced a cytopathic effect on day 7 of culture. Conclusions Even though daily contact with inanimate surfaces and patient fomites in contaminated areas may be a medium of infection, our data obtained in real-life conditions suggest that it might be less extensive than hitherto recognized.

Published
2020
Full Text
View/download PDF

42. Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020

Author

Colaneri, M., Sacchi, P., Zuccaro, V., Biscarini, S., Sachs, M., Roda, S., Pieri, T. C., Valsecchi, P., Piralla, A., Seminari, E., Matteo, A. D., Novati, S., Maiocchi, L., Pagnucco, L., Tirani, M., Baldanti, F., Mojoli, F., Perlini, S., Bruno, R., Mondelli, M. U., Brunetti, E., Mariani, B., Ludovisi, S., Lissandrin, R., Parisi, A., Patruno, S. F. A., Michelone, G., Gulminetti, R., Zanaboni, D., Maserati, R., Orsolini, P., Vecchia, M., Asperges, E., Filippo, A. D., Sambo, M., Lupi, M., Gallazzi, I., Alfano, C., Bonzano, M., Briganti, F., Crescenzi, G., Falchi, A. G., Guarnone, R., Guglielmana, B., Maggi, E., Martino, I., Pettenazza, P., di Marco, S. P., Quaglia, F., Sabena, A., Salinaro, F., Speciale, F., Zunino, I., de Lorenzo, M., Secco, G., Dimitry, L., Cappa, G., Maisak, I., Chiodi, B., Sciarrini, M., Barcella, B., Resta, F., Moroni, L., Vezzoni, G., Scattaglia, L., Boscolo, E., Zattera, C., Fidel, T. M., Vincenzo, C., Vignaroli, D., Bazzini, M., Iotti, G., Belliato, M., Perotti, L., Mongodi, S., Tavazzi, G., Marseglia, G., Licari, A., Brambilla, I., Daniela, B., Antonella, B., Patrizia, C., Giulia, C., Giuditta, C., Marta, C., Rossana, D., Milena, F., Bianca, M., Roberta, M., Enza, M., Stefania, P., Maurizio, P., Elena, P., Francesca, R., Antonella, S., Maurizio, Z., Marone, P., Guy, A., Laura, B., Ermanna, C., Giuliana, C., Luca, D., Gabriella, F., Gabriella, G., Alessia, G., Viviana, L., Claudia, L., Valentina, M., Simona, P., Marta, P., Alice, B., Giacomo, C., Irene, C., Alfonso, C., Raffella, D. M., Annapia, D. N., Alessandro, F., Guglielmo, F., Loretta, F., Federica, G., Alessandra, M., Novazzi, Federica, Giacomo, R., Beatrice, R., Maria, S. I., Monica, T., Edoardo, V. N., Calvi, M., Tizzoni, M., Nicora, C., Triarico, A., Petronella, V., Marena, C., Muzzi, A., Cutti, S., Novelli, V., Lago, P., Comandatore, F., Gaiarsa, S., Rettani, M., Bandi, C., and Ferrari, A.

Subjects
medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), LDH, Epidemiology, retrospective study, Severe disease, Disease, 030204 cardiovascular system & hematology, medicine.disease_cause, Teaching hospital, Betacoronavirus, 03 medical and health sciences, 0302 clinical medicine, Virology, Internal medicine, Pandemic, medicine, Humans, Viral, 030212 general & internal medicine, Pandemics, Coronavirus, severe disease, Reverse Transcriptase Polymerase Chain Reaction, business.industry, SARS-CoV-2, Teaching, Public Health, Environmental and Occupational Health, Outbreak, COVID-19, Retrospective cohort study, Pneumonia, Hospitals, Europe, Italy, Coronavirus Infections, Hospitals, Teaching, Pneumonia, Viral, business, Rapid Communication
Abstract

We describe clinical characteristics, treatments and outcomes of 44 Caucasian patients with coronavirus disease (COVID-19) at a single hospital in Pavia, Italy, from 21–28 February 2020, at the beginning of the outbreak in Europe. Seventeen patients developed severe disease, two died. After a median of 6 days, 14 patients were discharged from hospital. Predictors of lower odds of discharge were age > 65 years, antiviral treatment and for severe disease, lactate dehydrogenase > 300 mg/dL.

Published
2020

43. Tocilizumab for treatment of severe covid-19 patients: Preliminary results from smatteo covid19 registry (smacore)

Author

Colaneri, M., Bogliolo, L., Valsecchi, P., Sacchi, P., Zuccaro, V., Brandolino, F., Montecucco, C., Mojoli, F., Giusti, E. M., Bruno, R., Mondelli, M. U., Brunetti, E., Di Matteo, A., Seminari, E., Maiocchi, L., Pagnucco, L., Ludovisi, S., Lissandrin, R., Parisi, A., Patruno, S. F. A., Michelone, G., Gulminetti, R., Zanaboni, D., Novati, S., Maserati, R., Orsolini, P., Vecchia, M., Asperges, E., Di Filippo, A., Sambo, M., Biscarini, S., Lupi, M., Roda, S., Chiara Pieri, T., Gallazzi, I., Sachs, M., Perlini, S., Alfano, C., Bonzano, M., Briganti, F., Crescenzi, G., Giulia Falchi, A., Guarnone, R., Guglielmana, B., Maggi, E., Martino, I., Pettenazza, P., Di Marco, S. P., Quaglia, F., Sabena, A., Salinaro, F., Speciale, F., Zunino, I., De Lorenzo, M., Secco, G., Dimitry, L., Cappa, G., Maisak, I., Chiodi, B., Sciarrini, M., Barcella, B., Resta, F., Moroni, L., Vezzoni, G., Scattaglia, L., Boscolo, E., Zattera, C., Fidel, T. M., Vincenzo, C., Vignaroli, D., Bazzini, M., Iotti, G., Maurelli, M., Mongodi, S., Tavazzi, G., Belliato, M., Perotti, L., Aliberti, A. R., Amatu, A., Anfossi, L., Arisi, E., Baldi, C., Bellini, L., Benzi, A., Bichisao, G., Bolongaro, A., Andrea, B., Federica, B., Giacomo, B., Luca, C., Emanuele, C., Valeria, C., Fabrizio, C., Maria, C., Maria Paola, D., Elisa Lucia, D., Federica, F., Fiorenza, F., Marta, F., Marinella, F., Maddalena Margherita, G., Simonetta, G., Marcella, I., Claudia, L. C., Giuseppe, M., Benedetta, M. M., Simonetta, M., Maria, M. P., Maria, M. A., Federica, M., Larissa, N. T., Silvano, N., Anita, O., Michele, P., Debora, P., Simona, P., Raffaella, P., Silvia, P., Marco, P., Emanuela, P., Roberta, P., Danila Katia, R., Gianluca, R., Filippo, R., Francesca, R., Roberto, R., Giuseppe, R., Emanuela, R., Cristina, R., Giuseppe, S. G., Fabio, S., Debora, S., Giulia, T., Federico, V., Silvia, Z., Alessandro, B., Corrado, B., Chiara, B., Andrea, C., Costanza, C., Julia, N., Valentino, D., Roberto, D., Adelaide, G. M., Filippo, G., Andrea, P., Cecilia, Q., Andrea, S., Francesco, T., Chiara, D., Francesco, E., Bruno, L., Elisa, M., Maria Chiara, R., Barbara, R., Mariangela, S., Monica, T., Federica, V., Roberto, V., Marseglia, G., Licari, A., Brambilla, I., Baldanti, F., Barbarini, D., Bruno, A., Campanini, G., Cavanna, C., Comolli, G., Corbella, M., Daturi, R., Furione, M., Mariani, B., Marone, P., Paolucci, S., Parea, M., Percivalle, E., Piralla, A., Rovida, F., Sarasini, A., Zavattoni, M., Piero, M., Cambieri, P., Monzillo, V., Ardizzone, M., Bellotti, L., Brunco, V., Cabano, E., Casali, G., Capella, L., Devitis, D., Dossena, L., Frisco, G., Garbagnoli, G., Gardellini, F., Girello, A., Guerrizio, A., Landini, V., Lucchelli, C., Maliardi, V., Piemontese, P., Pezzaia, S., Premoli, M., Rebuffa, C., Bagnarino, J., Bergami, F., Bonetti, A., Caneva, G., Cassaniti, I., Corcione, A., Di Martino, R., Di Napoli, A., Ferrari, A., Ferrari, G., Fiorina, L., Gallone, A., Giardina, F., Girardi, A., Mercato, A., Novazzi, F., Ratano, G., Rossi, B., Saverimpilla, G., Sciabica, I. M., Tallarita, M., Nepita, E. V., Vitali, J., Cerino, A., Varchetta, S., Oliviero, B., Mantovani, S., Mele, D., Calvi, M., Tizzoni, M., Nicora, C., Triarico, A., Petronella, V., Marena, C., Muzzi, A., Lago, P., Cutti, S., Novelli, V., Comandatore, F., Biffignandi, G. B., Gaiarsa, S., Rettani, M., and Bandi, C.

Subjects
Microbiology (medical), medicine.medical_specialty, Azithromycin, Off label therapy, Microbiology, Article, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Tocilizumab, Virology, Internal medicine, Propensity score matching, Medicine, 030212 general & internal medicine, COVID-19 pneumonia, Adverse effect, lcsh:QH301-705.5, 030203 arthritis & rheumatology, business.industry, Mortality rate, Hydroxychloroquine, medicine.disease, Pneumonia, chemistry, lcsh:Biology (General), Cohort, ICU, tocilizumab, off label therapy, propensity score matching, mortality rate, business, medicine.drug
Abstract

Objective: This study aimed to assess the role of Tocilizumab therapy (TCZ) in terms of ICU admission and mortality rate of critically ill patients with severe COVID-19 pneumonia. Design: Patients with COVID-19 pneumonia were prospectively enrolled in SMAtteo COvid19 REgistry (SMACORE). A retrospective analysis of patients treated with TCZ matched using propensity score to patients treated with Standard Of Care (SOC) was conducted. Setting: The study was conducted at IRCCS Policlinico San Matteo Hospital, Pavia, Italy, from March 14, 2020 to March 27, 2020. Participants: Patients with a confirmed diagnosis of COVID-19 hospitalized in our institution at the time of TCZ availability. Interventions: TCZ was administered to 21 patients. The first administration was 8 mg/kg (up to a maximum 800 mg per dose) of Tocilizumab intravenously, repeated after 12 h if no side effects were reported after the first dose. Main Outcomes and Measures: ICU admission and 7-day mortality rate. Secondary outcomes included clinical and laboratory data. Results: There were 112 patients evaluated (82 were male and 30 were female, with a median age of 63.55 years). Using propensity scores, the 21 patients who received TCZ were matched to 21 patients who received SOC (a combination of hydroxychloroquine, azithromycin and prophylactic dose of low weight heparin). No adverse event was detected following TCZ administration. This study found that treatment with TCZ did not significantly affect ICU admission (OR 0.11; 95% CI between 0.00 and 3.38; p = 0.22) or 7-day mortality rate (OR 0.78; 95% CI between 0.06 and 9.34; p = 0.84) when compared with SOC. Analysis of laboratory measures showed significant interactions between time and treatment regarding C-Reactive Protein (CRP), alanine aminotransferase (ALT), platelets and international normalized ratio (INR) levels. Variation in lymphocytes count was observed over time, irrespective of treatment. Conclusions: TCZ administration did not reduce ICU admission or mortality rate in a cohort of 21 patients. Additional data are needed to understand the effect(s) of TCZ in treating patients diagnosed with COVID-19.

Published
2020

44. Rapid response to COVID-19 outbreak in Northern Italy: how to convert a classic infectious disease ward into a COVID-19 response centre

Author

Asperges, E., Novati, S., Muzzi, A., Biscarini, S., Sciarra, M., Lupi, M., Sambo, M., Gallazzi, I., Peverini, M., Lago, P., Mojoli, F., Perlini, S., Bruno, R., Mondelli, M.U., Brunetti, E., Di Matteo, A., Seminari, E., Maiocchi, L., Zuccaro, V., Pagnucco, L., Mariani, B., Ludovisi, S., Parisi, R.L.A., Sacchi, P., Patruno, S.F.A., Michelone, G., Gulminetti, R., Zanaboni, D., Maserati, R., Orsolini, P., Vecchia, M., Colaneri, M., Di Filippo, A., Roda, S., Pieri, T.C., Sachs, M., Valsecchi, P., Alfano, C., Bonzano, M., Briganti, F., Crescenzi, G., Falchi, A.G., Guarnone, R., Guglielmana, B., Maggi, E., Martino, I., Pettenazza, P., Pioli di Marco, S., Quaglia, F., Sabena, A., Salinaro, F., Speciale, F., Zunino, I., De Lorenzo, M., Secco, G., Dimitry, L., Cappa, G., Maisak, I., Chiodi, B., Sciarrini, M., Barcella, B., Resta, F., Moroni, L., Vezzoni, G., Scattaglia, L., Boscolo, E., Zattera, C., Fidel, T.M., Vincenzo, C., Vignaroli, D., Bazzini, M., Iotti, G., Belliato, M., Perotti, L., Mongodi, S., Tavazzi, G., Marseglia, G., Licari, A., Brambilla, I., Daniela, B., Antonella, B., Patrizia, C., Giulia, C., Giuditta, C., Marta, C., Rossana, D., Milena, F., Bianca, M., Roberta, M., Enza, M., Stefania, P., Maurizio, P., Elena, P., Antonio, P., Francesca, R., Antonella, S., Maurizio, Z., Guy, A., Laura, B., Ermanna, C., Giuliana, C., Luca, D., Gabriella, F., Gabriella, G., Alessia, G., Viviana, L., Claudia, L., Valentina, M., Simona, P., Marta, P., Alice, B., Giacomo, C., Irene, C., Corcione, A., di Martino, R., di Napoli, A., Alessandro, F., Guglielmo, F., Loretta, F., Federica, G., Alessandra, M., Federica, N., Giacomo, R., Beatrice, R., Maria, S.I., Monica, T., Edoardo, V.N., Calvi, M., Tizzoni, M., Nicora, C., Triarico, A., Petronella, V., and Marena, C.

Subjects
Microbiology (medical), 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Outbreak, General Medicine, Virology, Northern italy, Infectious Diseases, Infectious disease (medical specialty), Medicine, business, Rapid response
Published
2020

45. Detection of the SARS-CoV-2 in different biologic specimens from positive patients with COVID-19, in Northern Italy

Author

Novazzi, Federica, Cassaniti, Irene, Piralla, Antonio, Di Sabatino, Antonio, Bruno, Raffaele, Baldanti, Fausto, Mondelli, M, Brunetti, E, Di Matteo, A, Seminari, E, Maiocchi, L, Zuccaro, V, Pagnucco, L, Mariani, B, Ludovisi, S, Lissandrin, R, Parisi, A, Sacchi, P, Patruno, SFA, Michelone, G, Gulminetti, R, Zanaboni, D, Novati, S, Maserati, R, Orsolini, P, Vecchia, M, Sciarra, M, Asperges, E, Colaneri, M, Di Filippo, A, Sambo, M, Biscarini, S, Lupi, M, Roda, S, Pieri, TC, Gallazzi, I, Sachs, M, Valsecchi, P, Perlini, S, Alfano, C, Bonzano, M, Briganti, F, Crescenzi, G, Falchi, AG, Guarnone, R, Guglielmana, B, Maggi, E, Martino, I, Pettenazza, P, Pioli di Marco, S, Quaglia, F, Sabena, A, Salinaro, F, Speciale, F, Zunino, I, De Lorenzo, M, Secco, G, Dimitry, L, Cappa, G, Maisak, I, Chiodi, B, Sciarrini, M, Barcella, B, Resta, F, Moroni, L, Vezzoni, G, Scattaglia, L, Boscolo, E, Zattera, C, Tassi, MF, Capozza, V, Vignaroli, D, Bazzini, M, Iotti, G, Mojoli, F, Belliato, M, Perotti, L, Mongodi, S, Tavazzi, G, Marseglia, G, Licari, A, Brambilla, I, Barbarini, D, Bruno, A, Cambieri, P, Campanini, G, Cavanna, C, Comolli, G, Corbella, M, Daturi, R, Furione, M, Marone, P, Monzillo, E, Paolucci, S, Parea, M, Percivalle, E, Rovida, F, Sarasini, A, Zavattoni, M, Adzasehoun, G, Ardizzone, M, Bellotti, L, Brunco, V, Cabano, E, Casali, G, Capella, L, Devitis, D, Dossena, L, Frisco, G, Garbagnoli, G, Gardellini, F, Girello, A, Guerrizio, A, Landini, V, Lucchelli, C, Maliardi, V, Piemontese, P, Pezzaia, S, Premoli, M, Rebuffa, C, Zanello, C, Bagnarino, J, Bergami, F, Bonetti, A, Caneva, G, Corcione, A, Di Martino, R, Di Napoli, A, Ferrari, A, Ferrari, G, Fiorina, L, Gallone, A, Giardina, F, Girardi, A, Mercato, A, Ratano, G, Rossi, B, Saveriaempillai, G, Sciabica, IM, Tallarita, M, Vecchio Nepita, E, Vitali, J, Cerino, A, Varchetta, S, Oliviero, B, Mantovani, S, Mele, D, Calvi, M, Tizzoni, M, Nicora, C, Triarico, A, Petronella, V, Marena, C, Muzzi, A, Lago, P, Cutti, S, Novelli, V, Comandatore, F, Batisti Biffignandi, G, Gaiarsa, S, Rettani, M, and Bandi, C

Subjects
medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), education, Immunology, medicine.disease_cause, SARS‐CoV‐2, Covid‐19 in Children and Adolescents, 03 medical and health sciences, 2020 Update from The Italian Society of Pediatric Allergy and Immunology, 0302 clinical medicine, COVID‐19, Internal medicine, Epidemiology, transmission routes, medicine, Immunology and Allergy, 030212 general & internal medicine, Pediatrics, Perinatology, and Child Health, Coronavirus, swabs, specimen types, northern Italy, business.industry, SARS-CoV-2, COVID-19, medicine.disease, epidemiology, Northern italy, Pneumonia, 030228 respiratory system, Respiratory secretion, Nasal Swab, Pediatrics, Perinatology and Child Health, Supplement Article, business
Abstract

Coronavirus disease 2019 (COVID‐19) diagnosis is based on molecular detection of SARS‐CoV‐2 in respiratory samples such as nasal swab (NS) However, the evidence that NS in patients with pneumonia was sometimes negative raises the attention to collect other clinical specimens SARS‐CoV‐2 was shown in 10 3% rectal swabs (RS), 7 7% plasma, 1% urine, and 0% feces from 143 NS‐positive patients Potential infection by fluids different from respiratory secretion is possible but unlikely [ABSTRACT FROM AUTHOR] Copyright of Pediatric Allergy & Immunology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission However, users may print, download, or email articles for individual use This abstract may be abridged No warranty is given about the accuracy of the copy Users should refer to the original published version of the material for the full abstract (Copyright applies to all Abstracts )

Published
2020

46. CXCR3 and (alpha sub E beta sub 7) integrin identify a subset of CD8+ mature thymocytes that share phenotypic and functional properties with CD8+ gut intraepithelial lymphocytes

Author

Annunziato, F., Cosmi, L., Liotta, F., Lazzeri, E., Ramagnani, P., Angeli, R., Lasagni, L., Manetti, R., Marra, F., Gerard, C., Petrai, I., Dello Sbarba, P., Tonelli, F., Maggi, E., and Romagnani, S.

Subjects
CD8 lymphocytes -- Research, Integrins -- Research, Gastrointestinal mucosa -- Physiological aspects, Gastrointestinal mucosa -- Research, Health
Published
2006

47. Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing CoVID19 epidemics in Lombardy

Author

Rovida, F., primary, Cereda, D., additional, Novati, S., additional, Licari, A., additional, Triarico, A., additional, Marseglia, G.L., additional, Bruno, R., additional, Baldanti, F., additional, Mondelli, M., additional, Brunetti, E., additional, Di Matteo, A., additional, Seminari, E., additional, Maiocchi, L., additional, Zuccaro, V., additional, Pagnucco, L., additional, Mariani, B., additional, Ludovisi, S., additional, Lissandrin, R., additional, Parisi, A., additional, Sacchi, P., additional, Patruno, S.F.A., additional, Michelone, G., additional, Gulminetti, R., additional, Zanaboni, D., additional, Maserati, R., additional, Orsolini, P., additional, Vecchia, M., additional, Sciarra, M., additional, Asperges, E., additional, Colaneri, M., additional, Di Filippo, A., additional, Sambo, M., additional, Biscarini, S., additional, Lupi, M., additional, Roda, S., additional, Pieri, T.C., additional, Gallazzi, I., additional, Sachs, M., additional, Valsecchi, P., additional, Perlini, S., additional, Alfano, C., additional, Bonzano, M., additional, Briganti, F., additional, Crescenzi, G., additional, Falchi, A.G., additional, Guarnone, R., additional, Guglielmana, B., additional, Maggi, E., additional, Martino, I., additional, Pettenazza, P., additional, Pioli di Marco, S., additional, Quaglia, F., additional, Sabena, A., additional, Salinaro, F., additional, Speciale, F., additional, Zunino, I., additional, De Lorenzo, M., additional, Secco, G., additional, Dimitry, L., additional, Cappa, G., additional, Maisak, I., additional, Chiodi, B., additional, Sciarrini, M., additional, Barcella, B., additional, Resta, F., additional, Moroni, L., additional, Vezzoni, G., additional, Scattaglia, L., additional, Boscolo, E., additional, Zattera, C., additional, Tassi, M.F., additional, Capozza, V., additional, Vignaroli, D., additional, Bazzini, M., additional, Iotti, G., additional, Mojoli, F., additional, Belliato, M., additional, Perotti, L., additional, Mongodi, S., additional, Tavazzi, G., additional, Marseglia, G., additional, Brambilla, I., additional, Barbarini, D., additional, Bruno, A., additional, Cambieri, P., additional, Campanini, G., additional, Comolli, G., additional, Corbella, M., additional, Daturi, R., additional, Furione, M., additional, Monzillo, E., additional, Paolucci, S., additional, Parea, M., additional, Percivalle, E., additional, Piralla, A., additional, Rovida, F., additional, Sarasini, A., additional, Zavattoni, M., additional, Adzasehoun, G., additional, Bellotti, L., additional, Cabano, E., additional, Casali, G., additional, Dossena, L., additional, Frisco, G., additional, Garbagnoli, G., additional, Girello, A., additional, Landini, V., additional, Lucchelli, C., additional, Maliardi, V., additional, Pezzaia, S., additional, Premoli, M., additional, Bonetti, A., additional, Caneva, G., additional, Cassaniti, I., additional, Corcione, A., additional, Di Martino, R., additional, Di Napoli, A., additional, Ferrari, A., additional, Ferrari, G., additional, Fiorina, L., additional, Giardina, F., additional, Mercato, A., additional, Novazzi, F., additional, Ratano, G., additional, Rossi, B., additional, Sciabica, I.M., additional, Tallarita, M., additional, Vecchio Nepita, E., additional, Calvi, M., additional, Tizzoni, M., additional, Nicora, C., additional, Petronella, V., additional, Marena, C., additional, Muzzi, A., additional, and Lago, P., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results